This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Race Announces Presentation of Preclinical Breast Cancer Zantrene Study at the 2021 Hunter Cancer Research Symposium
5 November 2021– Race Oncology Limited (“Race”) congratulates Dr Joshua Brzozowski from the laboratory of Associate Professor Nikki Verrills, University of Newcastle, for winning the Best Poster Prize in the Biomarkers and Targeted Therapy section at the Hunter Cancer Research Symposium on November 4, 2021.
The presentation entitled “Preclinical efficacy of bisantrene for the treatment of breast cancer” describes the use of Zantrene® (bisantrene dihydrochloride) in breast cancer cells and identified two key highlights:
- Drug-resistant breast cancer cells are more sensitive to treatment with Zantrene compared to other anthracyclines, such as doxorubicin or epirubicin.
- Zantrene has additive or synergistic activity when used with cyclophosphamide (a widely used breast cancer drug) in human breast cancer cell lines.
This presentation expands on results previously reported from the Verrills Laboratory (ASX announcement: 9 March 2021).